PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

RN624 In Adult Patients With Chronic Low Back Pain

Phase 2

Completed

Conditions: Low Back Pain

Interventions: Drug: Placebo
Drug: PF-04383119 (RN624)
Drug: Naproxen

First Posted Date: 2008-01-02

Last Posted Date: 2021-07-12

Lead Sponsor: Pfizer

Target Recruit Count: 220

Registration Number: NCT00584870

Locations: 🇺🇸
Wake Internal Medicine Consultants, Inc., Raleigh, North Carolina, United States
🇺🇸
Pinnacle Research Group LLC, Anniston, Alabama, United States
🇺🇸
Radiant Research - Phoenix Southeast, Chandler, Arizona, United States

and more 33 locations

Treatment Use Study for Advanced Melanoma.

Conditions: Advanced Unresectable Melanoma

First Posted Date: 2008-01-02

Last Posted Date: 2009-12-14

Lead Sponsor: Pfizer

Registration Number: NCT00584493

Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: Etanercept
Other: Placebo

First Posted Date: 2007-12-27

Last Posted Date: 2012-04-23

Lead Sponsor: Pfizer

Target Recruit Count: 120

Registration Number: NCT00581555

Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Other: Placebo
Drug: PF-00572778
Drug: alprazolam

First Posted Date: 2007-12-24

Last Posted Date: 2009-09-14

Lead Sponsor: Pfizer

Target Recruit Count: 47

Registration Number: NCT00580190

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Aripiprazole
Other: Placebo
Drug: PF-00217830

First Posted Date: 2007-12-24

Last Posted Date: 2012-04-18

Lead Sponsor: Pfizer

Target Recruit Count: 164

Registration Number: NCT00580125

Locations: 🇺🇦
Pfizer Investigational Site, Lugansk, Ukraine

Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: CE-326,597
Drug: Placebo

First Posted Date: 2007-12-19

Last Posted Date: 2010-01-18

Lead Sponsor: Pfizer

Target Recruit Count: 41

Registration Number: NCT00576589

Locations: 🇺🇸
Pfizer Investigational Site, Willingboro, New Jersey, United States

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

Phase 3

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Bosutinib
Drug: imatinib

First Posted Date: 2007-12-17

Last Posted Date: 2019-01-08

Lead Sponsor: Pfizer

Target Recruit Count: 502

Registration Number: NCT00574873

Locations: 🇺🇸
Pacific Cancer Medical Center Inc, Anaheim, California, United States
🇺🇸
Robert A Moss, MD, FACP, Inc, Fountain Valley, California, United States
🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States

and more 159 locations

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Phase 2

Completed

Conditions: Ocular Hypertension
Primary Open-Angle Glaucoma

Interventions: Drug: Latanoprost Vehicle
Drug: PF-04217329 - Middle Dose
Drug: PF-4217329 - Highest Dose
Drug: PF-04217329 - Lowest Dose
Drug: PF-04217329 - Low Dose
Drug: Latanoprost 0.005%
Drug: PF-04217329 - High Middle Dose
Drug: PF-04217329 - High Dose
Drug: PF-04217329 - Vehicle

First Posted Date: 2007-12-13

Last Posted Date: 2021-04-30

Lead Sponsor: Pfizer

Target Recruit Count: 318

Registration Number: NCT00572455

Locations: 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸
Sall Research Medical Center, Artesia, California, United States
🇺🇸
North Bay Eye Associates, Inc., Petaluma, California, United States

and more 20 locations

Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus

Phase 4

Completed

Conditions: Pneumonia, Ventilator-Associated

Interventions: Drug: Linezolid
Drug: Vancomycin

First Posted Date: 2007-12-13

Last Posted Date: 2010-06-09

Lead Sponsor: Pfizer

Target Recruit Count: 149

Registration Number: NCT00572559

Locations: 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

Phase 2

Completed

Conditions: Insomnia

Interventions: Drug: PD 0200390
Drug: Placebo

First Posted Date: 2007-12-10

Last Posted Date: 2012-07-25

Lead Sponsor: Pfizer

Target Recruit Count: 682

Registration Number: NCT00569972

Locations: 🇨🇦
Pfizer Investigational Site, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy